Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

I agree with your assessment, but with some "minor" modifications:

1. K against certain solid tumors (phase 2)
1b. K against 1 or more certain solid tumors under BTD or some other accelerated program (phase 2/3)
1c. K against 1 (or maybe more) cancers under Orphan Drug (phase 2/3)
1d. K against a certain tumor(s) under surrogate or intermediate clinical endpoint and IMM (straight to Phase 4)
2. K + Cytarabine against AML (phase 1b)
3. K + Sunitinib against renal cancer (phase 1b/2)
4. K against retinoblastoma under Orphan Drug (phase 2/3)
5. B-ABSSSI (phase 3)
6. B-OM (phase 2/3)
7. P (phase 2/3)

The following trials could be further down the road:

1. K against lymphoma and multiple myeloma
2. B against diabetic foot ulcer
3. B-Ocular
4. B-Otic
5. Defensin-mimetics against Gram negative bacteria
6. Defensin-mimetics against candidiasis

CTIX partners one drug for $25 million to $50 million upfront and most of the above is paid.

Thanks for the list, Sox!